« Back
Home /
Vipivotide tetraxetan Ligand-Linker Conjugate

Vipivotide tetraxetan Ligand-Linker Conjugate

Item no.	HY-43869-250mg
Manufacturer	MedChem Express
CASRN	1703768-74-4
Amount	250 mg
Quantity options	100 mg 10mM*1 mL 10 mg 250 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.
Smiles	O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CN)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PSMA-617 Ligand-Linker Conjugate
Similar products	1703768-74-4
Available
Product Description	Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA)[1].
StorageTemperature	-20°C, 3 years (Powder)
Shipping	Blue Ice
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	655.74
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 125 mg/mL (ultrasonic)
Manufacturers Target	ADC Linker
Isoform	Non-cleavable Linker
Pathway	Antibody-drug Conjugate/ADC Related

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-43869-250mg-safety-datasheet.pdf